Search

Author/Creator Lee, Y.

2. 126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC). (December 2022)

Authors:
Frentzas, S.; Meniawy, T.; Kao, S.C-H.; Coward, J.; Clay, T.D.; Singhal, N.; Black, A.; Xu, W.; Kumar, R.; Lee, Y.; Lee, G-W.; Liao, W.; Zhong, D.; Shiah, H-S.; Chen, Y-M.; Gao, R.; Wang, R.; Zheng, H.; Tan, W.; Cho, E.K.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). (December 2022)

Authors:
Zhang, J.; Hussein, M.; Kao, S.C-H.; Clay, T.D.; Singhal, N.; Kim, H.R.; Cho, E.K.; Shim, B.; Lee, Y.; Lee, G-W.; Zhao, J.; Yu, Y.; Sun, M.; Lin, C-B.; Yang, T-Y.; Chang, G-C.; Zheng, H.; Tan, W.; Spigel, D.R.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy. (September 2015)

Authors:
Wong, A.; Wang, L.Z.; Wong, F.C.; Ow, S.; Nesaretnam, K.; Pang, A.; Tan, C.S.; Lim, Y.W.; Ho, G.F.; Lee, Y.; Yap, H.L.; Phang, S.; Alip, A.B.; Seng, K.Y.; Tai, B.C.; Walsh, R.; Goh, B.C.; Lee, S.C.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S295
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗